Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619764 | 0.83 | TP53 (0.43) | MAOBTP53MAPTSMN1; SMN2MTNR1B | |
| SCHEMBL21116465 | 0.83 | TP53 (0.46) | MAOBTP53MAPTSMN1; SMN2MTNR1B | |
| SCHEMBL18015849 | 0.81 | MTNR1A (0.45) | TP53MAPTSMN1; SMN2MTNR1BHTR1A | |
| SCHEMBL21116466 | 0.81 | TP53 (0.46) | MAOBTP53MAPTSMN1; SMN2MTNR1B | |
| SCHEMBL18014739 | 0.81 | TP53 (0.41) | MAOBTP53MAPTSMN1; SMN2MTNR1B | |
| SCHEMBL4996843 | 0.77 | MAOB (0.47) | MAOBTP53HTR1AHTR1DHTR2C | |
| SCHEMBL27279621 | 0.75 | MAOB (0.49) | MAOBTP53MAPTSMN1; SMN2HTR1A | |
| SCHEMBL30956100 | 0.74 | TP53 (0.40) | MAOBTP53MAPTSMN1; SMN2MTNR1B | |
| SCHEMBL17324189 | 0.74 | MTNR1A (0.40) | MAOBTP53MAPTSMN1; SMN2MTNR1B | |
| SCHEMBL20274083 | 0.74 | EPHX2 (0.41) | MAOBTP53MAPTSMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253755-B1 | NOVEL CYCLOPROPABENZOFURANYL PYRIDOPYRAZINEDIONES | PFIZER (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3126361-B1 | CHROMENE AND 1,1A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9765073-B2 | Cyclopropabenzofuranyl pyridopyrazinediones | PFIZER INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765073-B2 | Cyclopropabenzofuranyl pyridopyrazinediones | PFIZER INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170166566-A1 | SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170096428-A1 | Novel Cyclopropabenzofuranyl Pyridopyrazinediones | PFIZER INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170096428-A1 | Novel Cyclopropabenzofuranyl Pyridopyrazinediones | PFIZER INC. | 2017-04-06 | — | — | US | disclosed |
| EP-3126361-A1 | CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2016125048-A1 | NOVEL CYCLOPROPABENZOFURANYL PYRIDOPYRAZINEDIONES | PFIZER INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160222007-A1 | Novel Cyclopropabenzofuranyl Pyridopyrazinediones | PFIZER (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160222007-A1 | Novel Cyclopropabenzofuranyl Pyridopyrazinediones | PFIZER (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015150957-A1 | CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150274721-A1 | NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES | PFIZER (US) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274721-A1 | NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES | CYP4B1, CTRB1, CTRB2 | MAOB 55/4885TP53 1722/4885MAPT 4078/4885 |
| US-20160222007-A1 | Novel Cyclopropabenzofuranyl Pyridopyrazinediones | CYP4B1, RXRB, ADRA2B | MAOB 30/4885TP53 2026/4885MAPT 2441/4885 |
| US-20170166566-A1 | SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PRNP, MAOB | MAOB 3/4885TP53 836/4885MAPT 94/4885 |
| US-20170096428-A1 | Novel Cyclopropabenzofuranyl Pyridopyrazinediones | CYP4B1, RXRB, ADRA2B | MAOB 30/4885TP53 2026/4885MAPT 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.